Baillie Gifford & Co, acting on behalf of clients and funds under its management, declared to the AMF that on January 3 it had fallen below the threshold of 5% of the capital of Nanobiotix, following the sale of shares on the market.

The declarant stated that it held 1,739,697 Nanobiotix shares representing the same number of voting rights, i.e. 4.99% of the capital and 4.79% of the voting rights of this biotech company specializing in radiotherapy to combat cancer.

Copyright (c) 2023 CercleFinance.com. All rights reserved.